AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

a2 Milk’s unusual path to a top productivity ranking
Primary Sector

a2 Milk’s unusual path to a top productivity ranking

What explains a2's high productivity?: Branding, storytelling, and differentiation.

The ‘evolution’ in Synlait Milk’s strategy
Primary Sector

The ‘evolution’ in Synlait Milk’s strategy

It’s going to return to being a South Island processor.

FIF tax creator says ‘sorry’, but wants deeper reform
Policy

FIF tax creator says ‘sorry’, but wants deeper reform

Economist Peter Wilson says the Government's FIF changes need to go further.